Ovarian cancer cells use autophagy all of the time, but also lose several copies of autophagy genes resulting in a compromised capacity.
Not exact matches
The researchers then
used a combination of existing United States Food and Drug Administration - approved drugs to target autophagy and found
ovarian cancer cells to be highly sensitive to these drugs in several different mouse
cancer models — even among
cells resistant to standard chemotherapy.
Roswell Park
Cancer Institute (RPCI) researchers used deep T - cell receptor (TCR) sequencing to evaluate the clonal composition of TILs and identify novel prognostic biomarkers in ovarian c
Cancer Institute (RPCI) researchers
used deep T -
cell receptor (TCR) sequencing to evaluate the clonal composition of TILs and identify novel prognostic biomarkers in
ovarian cancercancer.
In lab experiments, the research team
used cell lines derived from 40 patient tumour samples to identify that CD151 contributes to the survival of
cells of high - grade serous
ovarian cancer origin.
Using the European Synchrotron Radiation Facility (ESRF), researchers analysed the effects of Organo - Osmium FY26 in
ovarian cancer cells — detecting emissions of X-ray fluorescent light to track the activity of the compound inside the
cells.
Top honors for both the 17 - to 18 - year - old category and the grand prize went to Shree Bose, who discovered that an energy protein of the
cell, AMP kinase, plays a role in developing resistance to a drug commonly
used to treat
ovarian cancer.
Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for
Cancer Research, Lausanne, the study shows that
ovarian tumors harbor highly reactive killer T
cells — which kill infected and cancerous
cells — and demonstrates how they can be identified and selectively grown for
use in personalized,
cell - based immunotherapies.
First, we produced PARP1 - KO
ovarian cancer cell lines
using CRISPR / Cas9 gene editing to test the loss of PARP - 1 as a resistance mechanism to all clinically
used PARP inhibitors.
Roswell Park Comprehensive
Cancer Center researchers used deep T - cell receptor (TCR) sequencing to evaluate the clonal composition of TILs and identify novel prognostic biomarkers in ovarian c
Cancer Center researchers
used deep T -
cell receptor (TCR) sequencing to evaluate the clonal composition of TILs and identify novel prognostic biomarkers in
ovarian cancercancer.
David Lampi Hermanson, Ph.D., a 2014 - 2017 CRI postdoctoral fellow at the University of Minnesota, is investigating the
use of natural killer (NK)
cell - based immunotherapy for
ovarian cancer.
Tanyi said he is eager to explore whether the dendritic -
cell vaccine might also be
used as a first - line treatment for women who are newly diagnosed with
ovarian cancer.
$ 1.8 M Supports
Cancer Drug Discovery on Commonly Mutated Gene New Brunswick Patch — April 5, 2016 Behavioral Scientist Shares Insights about FDA's Proposed Rule on Banning Tanning Bed
Use among Minors News-Medical.net - March 19, 2016 Intervention Program Reduces Caregiver Distress during Hospitalization of Pediatric Stem
Cell Transplant Patients News-Medical.net - March 9, 2016 Exploring Genomic Pathways in the Development of
Ovarian Cancer GMNews.com - March 2, 2016 Differences in Type of Small Protein may further Elucidate Lung
Cancer Risk in African Americans ScienceDaily.com - March 2, 2016 Study Looks at Post-Treatment Resources for Prostate
Cancer Patients Transitioning to Survivorship News-Medical.net - February 11, 2016 Drawing the Line on Tanning Bed
Use by Teens ScienceDaily.com - December 21, 2015 What Rutgers Study Uncovered about E-Cigarette
Use NJBiz.com - December 9, 2015 Identification of Barrier that Prevents Progression of Benign Kidney Tumors to Malignant Disease MedicalNewsToday.com - November, 24, 2015 What is the Color of the Lung
Cancer Ribbon?
The
use of two drugs never tried in combination before in
ovarian cancer resulted in a 70 percent destruction of
cancer cells already resistant to commonly
used chemotherapy agents, say researchers at Mayo Clinic in Florida.
The team has tested its triple threat nanoparticles, containing drugs typically
used to treat
ovarian cancer (such as doxorubicin, cisplatin and camptothecin), against lab - grown
ovarian cancer cells.
Olaparib is a PARP inhibitor, which is already
used to treat certain
ovarian cancer patients and prevents damaged
cancer cells from repairing themselves after chemotherapy or radiotherapy.
The first step was to understand the biological signals that attract
ovarian cancer cells to the omentum and
use it for rapid growth.
Using state - of - the - art proteomics and associated computational methods, the Speicher laboratory is investigating protein changes associated with
ovarian cancer, melanoma, cardiac injury resulting from breast
cancer therapies, ectopic pregnancy, red
cell diseases, and other clinical disorders.
February 10, 2015 New screening tool could speed development of
ovarian cancer drugs University of Chicago Medicine researchers have built a model system that
uses multiple
cell types from patients to rapidly test compounds that could block the early steps in
ovarian cancer metastasis.
University of Chicago Medicine researchers have built a model system that
uses multiple
cell types from patients to rapidly test compounds that could block the early steps in
ovarian cancer metastasis.